The FOCUS Trial

The FOCUS trial is assessing whether cognitive behaviour therapy (CBT) is an effective treatment for individuals who have experience of psychosis and whose symptoms have been unresponsive to the anti-psychotic medication ‘clozapine’.  Greater Manchester West Mental Health NHS Foundation Trust, details on the trial can be found here:

The FOCUS statistical analysis plan is available for download here

The FOCUS economic evaluation protocol is available for download here

The MAPS Trial

Psychosis is a mental health problem that causes people to perceive or interpret things differently from those around them. Common symptoms of psychosis are unusual beliefs (delusions) and hallucinations (most often, hearing voices). Antipsychotics are the standard medication for these problems and are often helpful but can have serious side effects. There is also evidence that talking therapies (such as cognitive behaviour therapy (CBT) or family intervention) can help reduce symptoms and prevent relapse. The guidelines suggest that treatment options should include the possibility of choice between CBT, antipsychotic medication or both. However, more research is needed to see how well psychological treatment works when used alone, compared with antipsychotic medication and compared with psychological treatment and antipsychotic medication combined. The first stage to better understanding what is most helpful is to conduct a small study to see if young people and their families want to take part in this kind of research and to find out what they think of taking part. This will show whether a larger study should be done and the best way to do it. Managing Adolescent first episode Psychosis: a feasibility Study (MAPS) has been funded by the National Institute for Health Research (NIHR) Health Technology Assessment (HTA) programme to answer the question of whether it is feasible to conduct a study to examine the effectiveness of psychological therapy, antipsychotic medication or a combination of the two, in adolescents with first episode psychosis. ISRCTN Registry number: ISRCTN80567433.

 

The MAPS statistical analysis plan is available for download here

 

The EMPOWER Trial

 

The EMPOWER trial, funded by the NIHR HTA Programme and the Australian Government National Health and Medical Research Council, will evaluate the EMPOWER App against treatment as usual, using a multicentre, two arm, parallel group, cluster randomised controlled design involving eight purposively selected Community Mental Health Services (6 in Glasgow and 2 in Melbourne).  Eligible patients are adults with a diagnosis of Schizophrenia-related disorder who have either been admitted to a psychiatric in-patient service at least once in the previous two years for relapse of psychosis or have received crisis intervention in the previous two years for a relapse of psychosis. The primary outcome is relapse over a 12 month follow-up period.

 

The EMPOWER statistical analysis plan is available for download here